GSK -FDA Advisory Committee recommends approval of BREO ELLIPTA for the treatment of COPD
ENP Newswire - 18 April 2013
Release date- 17042013 - GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against)*.
BREO ELLIPTA, is the proposed proprietary name for FF/VI 100/25 mcg, a combination of the inhaled corticosteroid (ICS) fluticasone furoate 'FF' and the long acting bronchodilator (LABA) vilanterol 'VI' (FF/VI).
The FDA Advisory Committee also voted that the safety of FF/VI 100/25 mcg once daily in COPD has been adequately demonstrated for the proposed indications (10 for, 3 against).Patrick Vallance, GSK's President of Pharmaceuticals, R&D, said: 'We are pleased with the outcome of today's meeting. COPD is a debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives. This positive recommendation is a crucial first step towards making BREO ELLIPTA available for appropriate COPD patients across the US. We look forward to a final decision from the FDA later this year.''After a decade of development in this programme, our collaboration with GSK is one step closer to providing an important therapeutic option to COPD patients,' said Rick E Winningham, Chief Executive Officer of Theravance. 'We are proud to collaborate with GSK on the development and potential commercialisation of treatments for COPD and other respiratory diseases.
The panel's positive recommendation of BREO ELLIPTA represents an important achievement in a transformative year for Theravance.'In July 2012, a New Drug Application (NDA) was submitted to the FDA for the use of BREO administered by the ELLIPTA inhaler for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. In June 2012, a regulatory application for FF/VI was submitted in the European Union under the trade name RELVAR for the treatment of patients with COPD and asthma. In the United States, BREO ELLIPTA is not proposed for the relief of acute bronchospasm or for the treatment of asthma. GSK and Theravance are reviewing the strategy for a future US filing for asthma.The FDA Advisory Committee provides non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.
The Prescription Drug User Fee Act (PDUFA) goal date for FF/VI is 12 May 2013.Safety Information
The adverse event profile of FF/VI was generally consistent with the known class effects of an ICS/LABA combination and the cardiovascular safety profile of VI and FF/VI was broadly consistent with the known pharmacology of LABAs in patients with COPD. Across the four pivotal COPD studies for BREO ELLIPTA, the most frequently reported adverse events in the FF/VI arms included nasopharyngitis, headache, upper respiratory tract infection, oropharyngeal candidiasis COPD, back pain, pneumonia, bronchitis and sinusitis. COPD exacerbation was the most common serious adverse event reported followed by pneumonia.About COPD
Chronic obstructive pulmonary disease (COPD) is a term referring to two lung diseases, chronic bronchitis and emphysema, that are characterized by obstruction to airflow that interferes with normal breathing. COPD is the third most common cause of death in the US and The National Heart, Lung and Blood Institute (NHLI) estimates that 13 million US adults have COPD and another 11 million are undiagnosed or developing COPD. (American Lung Association, COPD Fact Sheet, February 2011).According to the NHLI, long-term exposure to lung irritants that damage the lungs and the airways are usually the cause of COPD and in the United States, the most common irritant that causes COPD is cigarette smoke. Breathing in second hand smoke, air pollution, or chemical fumes or dust from the environment or workplace also can contribute to COPD. Most people who have COPD are at least 40 years old when symptoms begin.COPD-related exacerbations are typically defined as a worsening of symptoms that require medical intervention.
A high rate of exacerbations is associated with significant disease progression.About BREO ELLIPTA or RELVAR
FF/VI, previously referred to as RELOVAIR, is an investigational medicine and is not currently approved anywhere in the world. Other Respiratory Development Programmes:
BREO ELLIPTA is one of several late-stage assets in the GSK respiratory development portfolio, which includes LAMA/LABA (UMEC/VI, with proposed brand name ANORO ELLIPTA), VI monotherapy and MABA (GSK961081), developed in collaboration with Theravance, as well as GSK's investigational medicines FF monotherapy, UMEC monotherapy and anti-IL5 MAb (mepolizumab). These investigational medicines are not currently approved anywhere in the world.ANORO, RELVAR, BREO and ELLIPTA are trademarks of the GlaxoSmithKline group of companies. The use of these brand names is not approved by any regulatory authorities.
[Editorial queries for this story should be sent to email@example.com]
((Comments on this story may be sent to firstname.lastname@example.org))